Ana Luiza Maia

About Ana Luiza Maia

Ana Luiza Maia, With an exceptional h-index of 50 and a recent h-index of 31 (since 2020), a distinguished researcher at Universidade Federal do Rio Grande do Sul, specializes in the field of Thyroid hormone metabolism, Low T3 syndrome, MEN 2 syndromes, Thyroid carcinomas.

His recent articles reflect a diverse array of research interests and contributions to the field:

Not Only RET but NF1 and Chromosomal Instability Are Seen in Young Patients with Sporadic Medullary Thyroid Carcinoma

Survival Outcomes in Thyroid Cancer Patients with Co-Occurring Breast Cancer: Evidence of Mortality Risk Attenuation

Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective

Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids

Differentiated thyroid carcinoma: what the nonspecialists needs to know

Age-related variation in malignant cytology rates of thyroid nodules: insights from a retrospective observational study assessing the ACR TI-RADS

Classification of thyroid tumors based on DNA methylation patterns

EO2401 (E) peptide immunotherapy+ nivolumab (N)+/-bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.

Ana Luiza Maia Information

University

Position

Hospital de Clinicas de Porto Alegre

Citations(all)

11057

Citations(since 2020)

5149

Cited By

8010

hIndex(all)

50

hIndex(since 2020)

31

i10Index(all)

136

i10Index(since 2020)

89

Email

University Profile Page

Google Scholar

Ana Luiza Maia Skills & Research Interests

Thyroid hormone metabolism

Low T3 syndrome

MEN 2 syndromes

Thyroid carcinomas

Top articles of Ana Luiza Maia

Not Only RET but NF1 and Chromosomal Instability Are Seen in Young Patients with Sporadic Medullary Thyroid Carcinoma

Journal of the Endocrine Society

2024/6

Survival Outcomes in Thyroid Cancer Patients with Co-Occurring Breast Cancer: Evidence of Mortality Risk Attenuation

Clinical Breast Cancer

2024/4/6

Rafael Selbach Scheffel
Rafael Selbach Scheffel

H-Index: 13

Ana Luiza Maia
Ana Luiza Maia

H-Index: 27

Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective

2024/2

Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids

Oncogene

2024/1/12

Differentiated thyroid carcinoma: what the nonspecialists needs to know

2024

Ana Luiza Maia
Ana Luiza Maia

H-Index: 27

Age-related variation in malignant cytology rates of thyroid nodules: insights from a retrospective observational study assessing the ACR TI-RADS

European Journal of Endocrinology

2023/12

Rafael Selbach Scheffel
Rafael Selbach Scheffel

H-Index: 13

Ana Luiza Maia
Ana Luiza Maia

H-Index: 27

Classification of thyroid tumors based on DNA methylation patterns

Thyroid

2023/9/1

Mariana Recamonde-Mendoza
Mariana Recamonde-Mendoza

H-Index: 11

Ana Luiza Maia
Ana Luiza Maia

H-Index: 27

EO2401 (E) peptide immunotherapy+ nivolumab (N)+/-bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.

2023/6/1

Active surveillance of differentiated thyroid cancer metastatic cervical lymph nodes: a retrospective single-center cohort study

Thyroid

2023/3/1

Rafael Selbach Scheffel
Rafael Selbach Scheffel

H-Index: 13

Ana Luiza Maia
Ana Luiza Maia

H-Index: 27

Papillary thyroid microcarcinoma: insights from a cohort of 257 thyroidectomized patients

Hormone and Metabolic Research

2023/3

Demographic and clinical features of pediatric vasculitis: a single-center study

ARP Rheumatol

2023/1/1

Pheochromocytomas and hypertension

2023/1/1

Ana Luiza Maia
Ana Luiza Maia

H-Index: 27

An undetectable postoperative calcitonin level is associated with long-term disease-free survival in medullary thyroid carcinoma: Results of a retrospective cohort study

Thyroid

2023/1/1

Rafael Selbach Scheffel
Rafael Selbach Scheffel

H-Index: 13

Ana Luiza Maia
Ana Luiza Maia

H-Index: 27

Ctim-17. Eo2401 Therapeutic Vaccine for Patients with Recurrent Glioblastoma: Phase 1/2 Rosalie Study (NCT04116658)

Neuro-Oncology

2022/11/1

642 EO2401 microbiome derived therapeutic vaccine+ nivolumab, with/without standard continuous, or low-dose symptom directed, bevacizumab, in recurrent glioblastoma: phase 1–2 …

2022/11/1

Effect of COVID-19 pandemic on diagnosis and treatment of thyroid cancer in Brazil

Frontiers in Endocrinology

2022/10/5

Effect of Suppressive Levothyroxine Therapy on Bone Mineral Density in Young Patients with Differentiated Thyroid Carcinoma

Metabolites

2022/9/7

Rafael Selbach Scheffel
Rafael Selbach Scheffel

H-Index: 13

Ana Luiza Maia
Ana Luiza Maia

H-Index: 27

303P EO2401 (EO) therapeutic vaccine for patients (pts) with recurrent glioblastoma (GB): Phase I/II ROSALIE study

Annals of Oncology

2022/9/1

Overall survival for HER2-positive breast cancer patients in the HER2-targeted era: evidence from a population-based study

Clinical Breast Cancer

2022/7/1

Ana Luiza Maia
Ana Luiza Maia

H-Index: 27

See List of Professors in Ana Luiza Maia University(Universidade Federal do Rio Grande do Sul)

Co-Authors

academic-engine